En
En
Fr
Fr
De
De
It
It
Es
Es
Cn
Cn

16 JAHRE DER INTERNATIONALEN KLINISCHEN PRAXIS BEI TRANSPLANTATION VON MENSCHLICHEN EMBRYONALEN/FETALEN  STAMMZELLEN

WELTGRÖSSTE KLINISCHE PRAXIS BEI TRANSPLANTATION VON EMBRYONALEN STAMMZELLEN FÜR BEHANDLUNG VERSCHIEDENER ERKRANKUNGEN UND ZUSTÄNDEN

Startseite
Info uber EmCell
Info uber Zellentherapie
Unsere Erfahrungen
Liste von Krankheiten:
Maligne Erkrankungen
Zuckerkrankheit
Nervenkrankheiten
Alterungsprobleme
Immunodefizitzustände
Endoskopische Behandlung von Lebererkrankungen
Kongresse und Konferenzen
Video und andere Materialien
FAQs
E-Mail

Method of Treatment of Acquired Immune Deficiency Syndrome...



Method of Treatment of Acquired Immune Deficiency Syndrome with Embryonic Hematopoietic Stem Ñells

 

A.I. Smikodub, Cell Therapy Clinic of National Medical University and Embryonic Tissues Center EmCell, Kiev, Ukraine

 

This method is protected by two US patents: ¹ 5,811,089 from Sep. 22, 1998 and  US 6,184,033 B1 from Feb.6, 2001, Dutch patent ¹ 194908 from Sep.15, 2003, and Russian patent ¹ 2137484 from Sep.20, 1999. It allows for stabilization and restoration of functional activity of the immune system and compensation of insufficient immune response of the patient with simultaneous decrease of clinical manifestations of the disease.   The main group consisted of 48 patients for whom preliminary selection criteria have been developed: impossibility of antiviral therapy due to intolerance or considerable side effects; more than 50% decrease in CD4+ during preceding 6 months or reduction by 100/1 mm3 during the same time; disease progression: transition from HIV to AIDS-AC, and from AIDS-AC into AIDS despite anti-virus therapy; impaired workability and quality of life (decrease in Karnofsky index by more than 20% during last 6 months); CD4+ count less than 50/mm3 with manifestations of AIDS-indicator diseases, and with Karnofsky index below 30%.

 

Developed is an original cell composition containing embryonic hematopoietic stem cells. Its application led to increase of immune indices  including CD4, CD3, CD8 subpopulations; the most demonstrative was this increase in the group of patients with CD4+ count 200-300 mm3: at the end of the first post-transplant week, it rose by 35%, second week – by 72%, and in 1 and 6 months it was higher by respectively 51% and 42%.  High levels of lymphocytes were maintained in patients in 3-6 and even in 10-12 months after transplantation.  Reported were also normalization of peripheral blood count (leukocytes, erythrocytes, thrombocytes), decrease in infectious complications and manifestations of peripheral neuropathy and related neurological symptoms, disappearance of astheno-neurotic syndrome, optimization of psychoemotional state with decrease of depression signs, improvement of mental and physical activity, weight gain, and substantial inhibition of the progression of the disease.


Nachrichte
2008-09-30
Prof. Alexander I. Smikodub nahm an dem Europaeischen Kongress zu “Anti-Aging und ästhetische Medizin” teil, der am 11. -14. September 2008 in Düsseldorf

Prof. Alexander I. Smikodub nahm an dem Europaeischen Kongress zu “Anti-Aging und ästhetische Medizin” teil, der am 11. -14. September 2008 ...
  Andere Nachrichte
 
Artikeln

25. Suspensionen mit embryonalen Stammzellen bei der Behandlung der soliden Tumoren vor dem Beginn der Haupttherapie.

Autor: Alexandr Smykodub   Klinik für zelluläre Therapie bei der Nationalen medizinischen Universität und dem Embryonic Tissues Center «EmCell»   Den Patienten mit soliden Tumoren und Komplikationen, wegen deren die ...
  Andere Artikeln
 
Patente

Arzneipräparat auf der Basis der fötalen Zellensuspension mit Immunsubstitutionseffekt, für Behandlung von AIDS (HIV-Infektion). Erfinder: Alexandr Iwanowitsch Smykodub. USA-Patent Nr.6,184,033 81 von ...
   
 
Copyright © 1999-2009 EmCell.com